Quick answer
Angiomyolipoma is a benign kidney tumor made of blood vessels, muscle and fat. It is found in about 0.44% of people, and the fat inside it usually allows the diagnosis on imaging.1 Most of the time it is only monitored. Treatment comes in when there is persistent pain, bleeding, a very large tumor or another risk situation, and sparing the kidney is preferred.1,4
What it is
Classic angiomyolipoma is a benign tumor that grows from the kidney's supporting tissue. The name combines its three parts: blood vessels (angio), muscle (myo) and fat (lipo).1
It is found in about 0.44% of people: 0.6% of women and 0.3% of men. Only 5% have more than one tumor. It can occur on its own or as part of tuberous sclerosis, a genetic disease.1
There is a rare variant, epithelioid angiomyolipoma, which usually appears around age 50. Unlike the classic form, it can behave aggressively.1
How it shows up on scans
Angiomyolipoma is often found on an ultrasound, CT or MRI done for another reason. The fat inside it usually confirms the diagnosis.1
When the tumor has little fat, imaging cannot reliably tell it apart from kidney cancer.1,2 A needle biopsy is rarely helpful. When the assessment does not clearly show that the tumor is benign, the European guideline recommends managing it as kidney cancer.1

The other findings are on the kidney masses and cysts page.
Symptoms and bleeding
Angiomyolipoma usually grows slowly and causes no symptoms. Larger ones can cause local pain.1
The main complication is spontaneous bleeding, when the tumor ruptures. Blood can collect around the kidney or pass into the urine, and this bleeding can be serious. The risk seems higher in large tumors, in those with more blood vessels and in people with tuberous sclerosis.1
The 4 cm cutoff
For a long time, 4 cm was the size at which treatment was recommended. The European guideline says the link between size and bleeding is unclear, and that 4 cm alone should not lead to treatment.1 A study of patients under surveillance reached the same conclusion: most tumors larger than 4 cm can start with monitoring.5
Monitoring
For most angiomyolipomas, monitoring with imaging is the most appropriate approach. In the review behind the guideline, 11% of monitored tumors grew, 2% bled and 5% of patients needed treatment.1,4
When to treat
The European guideline recommends treatment in these situations:1
- A large tumor (there is no set size for this)
- A woman of childbearing age
- Someone who cannot keep up with monitoring or would not have quick access to emergency care
- Persistent pain
- Acute or repeated bleeding
People at high risk of abdominal trauma may also be offered treatment.1
Treatment options
| Option | What the guideline and studies say |
|---|---|
| Kidney-sparing surgery | Preferred when surgery is indicated and feasible. Second treatment in 0.85% of cases1,4 |
| Embolization | Blocks the tumor's blood vessels through a catheter. Less invasive, with a second treatment in 31%. An option for serious bleeding1,4 |
| Ablation | Destroys the tumor with heat or cold. Limited data1 |
| Everolimus | A medicine that shrinks the tumor in tuberous sclerosis. Indicated when surgery and embolization are not possible1,6 |
Kidney-sparing surgery removes only the tumor. It can often be done with robotic partial nephrectomy.
In angiomyolipoma that occurs without tuberous sclerosis, a small study of 20 patients showed a tumor reduction of 25% or more with everolimus in 71.4% at six months. But 20% left the study because of toxicity, and 40% withdrew because of side effects.1,7
Tuberous sclerosis
Tuberous sclerosis is a genetic disease caused by changes in the TSC1 or TSC2 genes, passed from parent to child. It is rare: 1 to 9 people in every 100,000.3 In this disease, angiomyolipomas are often multiple and in both kidneys.1
In tuberous sclerosis, angiomyolipoma can appear in enlarged lymph nodes, and this is not metastasis.1 In controlled trials, everolimus reduced the size of the tumors.1,6 The European guideline recommends looking for other signs of tuberous sclerosis in people with angiomyolipoma.2
How I approach it
I read the images together with the report and go over monitoring, embolization or surgery with the patient. When I monitor a small angiomyolipoma, I repeat the imaging once a year. When surgery is indicated, robotic partial nephrectomy removes only the tumor. In my practice, the hospital stay is usually less than 24 hours, the catheter comes out before discharge and, in most cases, no drain is left.
When to see a urologist
- If the report mentions angiomyolipoma or a fat-containing kidney mass
- If the report says the mass has little fat or that imaging is not conclusive
- If you have flank pain that does not go away
- If you see blood in the urine
- If you have sudden, severe pain in the flank or back, with dizziness or weakness: this needs immediate evaluation
Frequently asked questions
Is angiomyolipoma cancer?+
No. Classic angiomyolipoma is a benign kidney tumor made of blood vessels, muscle and fat.1 There is a rare variant, epithelioid angiomyolipoma, that can behave aggressively.1
Does an angiomyolipoma larger than 4 cm need surgery?+
Not necessarily. The European guideline says the traditional 4 cm cutoff should not by itself lead to treatment, because the link between size and the risk of bleeding is unclear.1,5
Can an angiomyolipoma bleed?+
Yes. Spontaneous bleeding is the main complication and can be serious. The risk seems higher in large tumors, in those with many blood vessels and in people with tuberous sclerosis.1 In one group of patients under surveillance, 2% had bleeding.1,4
What does monitoring involve?+
Regular imaging tests. In my practice, for a small angiomyolipoma, I repeat the scan once a year. Monitoring is the most appropriate approach for most angiomyolipomas. Among patients under surveillance, 11% of tumors grew and 5% of patients needed treatment.1,4
What is the treatment when it needs to be treated?+
Surgery that removes only the tumor and spares the kidney, when feasible, or embolization, which blocks the tumor's blood vessels. Embolization is less invasive but more often needs a second treatment.1,4 In tuberous sclerosis, everolimus can shrink the tumors.1,6
References
- EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2026. Epidemiology, aetiology and pathology chapter (classical angiomyolipoma). EAU
- EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2026. Diagnostic evaluation chapter. EAU
- EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2026. Hereditary and syndrome-specific RCC chapter. EAU
- Fernández-Pello S, Hora M, Kuusk T, et al. Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. Eur Urol Oncol. 2020;3(1):57-72. PubMed
- Bhatt JR, Richard PO, Kim NS, et al. Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4cm Can Be Offered Active Surveillance as an Initial Management Strategy. Eur Urol. 2016;70(1):85-90. PubMed
- Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS One. 2017;12(8):e0180939. PubMed
- Geynisman DM, Kadow BT, Shuch BM, et al. Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial. J Urol. 2020;204(3):531-537. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation
